O
Olimpia Finizio
Publications - 13
Citations - 1367
Olimpia Finizio is an academic researcher. The author has contributed to research in topics: Acute promyelocytic leukemia & Internal medicine. The author has an hindex of 7, co-authored 9 publications receiving 1151 citations.
Papers
More filters
Journal ArticleDOI
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
Francesco Lo-Coco,Giuseppe Avvisati,Marco Vignetti,Christian Thiede,Simona Iacobelli,Felicetto Ferrara,Paola Fazi,Laura Cicconi,E. Di Bona,Giorgina Specchia,Simona Sica,Mariadomenica Divona,Alessandro Levis,Walter Fiedler,Elisa Cerqui,Massimo Breccia,Giuseppe Fioritoni,Mario Cazzola,L. Melillo,Enrica Morra,Bernd Hertenstein,Mohammed Wattad,Michael Lübbert,Mathias Hänel,Norbert Schmitz,Alessandro Rambaldi,G. La Nasa,Mario Luppi,Fabio Ciceri,Olimpia Finizio,Adriano Venditti,Francesco Fabbiano,Konstanze Döhner,M. Sauer,Arnold Ganser,Sergio Amadori,Franco Mandelli,Hartmut Döhner,Gerhard Ehninger +38 more
TL;DR: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.
Journal ArticleDOI
Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes
Fabio Efficace,Franco Mandelli,Giuseppe Avvisati,Francesco Cottone,Felicetto Ferrara,Eros Di Bona,Giorgina Specchia,Massimo Breccia,Alessandro Levis,Simona Sica,Olimpia Finizio,Maria Grazia Kropp,Giuseppe Fioritoni,Elisa Cerqui,Marco Vignetti,Sergio Amadori,Richard F. Schlenk,Uwe Platzbecker,Francesco Lo-Coco +18 more
TL;DR: Overall, current HRQOL findings further support the use of ATRA plus arsenic trioxide as preferred first-line treatment in patients with low- or intermediate-risk APL.
Journal ArticleDOI
A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study
Patrizia Chiusolo,Gesine Bug,Attilio Olivieri,Mats Brune,Nicola Mordini,Paolo Emilio Alessandrino,Alida Dominietto,Anna Maria Raiola,Carmen Di Grazia,Francesca Gualandi,Maria Teresa Van Lint,Felicetto Ferrara,Olimpia Finizio,Emanuele Angelucci,Andrea Bacigalupo +14 more
TL;DR: The original PT-CY regimen can be modified with CsA on day 0, still providing protection against GVHD, low toxicity, and encouraging low relapse incidence in AML patients, also over 60 years of age.
Journal Article
Autologous Stem Cell Transplantation for Patients with Acute Promyelocytic Leukemia in Second Molecular Remission
Felicetto Ferrara,Olimpia Finizio,Tiziana Izzo,Cira Riccardi,Clelia Criscuolo,Antonella Carbone,Erika Borlenghi,Giuseppe Rossi +7 more
TL;DR: The results suggest that ASCT performed with a molecularly negative graft in APL patients in second MR offers a valid chance for achieving a cure and should also be considered in relapsed patients with an HLA-compatible donor.
Journal Article
Acute Promyelocytic Leukemia in Patients Aged Over 60 Years: Multicenter Experience of 34 Consecutive Unselected Patients
Felicetto Ferrara,Olimpia Finizio,Alfonso Maria D'Arco,Lucia Mastrullo,Nicola Cantore,Pellegrino Musto +5 more
TL;DR: The data demonstrate that at least 30% of older APL patients are not eligible to accrual in multicenter trials; furthermore, in this subset, the possibility of early death is substantial; however, when CR is achieved, a personalized consolidation approach can be adopted with theossibility of achieving long-term disease control.